Related Experiment Video

Updated: Nov 18, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Stool Swap Overcomes PD-1 Resistance

    Cancer Discovery
    |February 11, 2021
    PubMed

    Insights

    Fecal transplants can restore sensitivity to immunotherapy in melanoma patients. Modulating gut bacteria shows promise for improving responses to anti-PD-1 therapies.

    Area of Science:

    • Oncology
    • Microbiome Research
    • Immunotherapy

    Background:

    • Melanoma often becomes resistant to checkpoint blockade therapies.
    • Gut bacteria modulation, via fecal transplants, can re-sensitize refractory melanomas.

    Discussion:

    • Fecal microbiota transplantation (FMT) enhances anti-PD-1 efficacy in non-responsive melanoma.
    • The gut microbiome's role in immunotherapy response is a critical area of investigation.

    Key Insights:

    • Fecal transplants can overcome resistance to checkpoint inhibitors in melanoma.
    • Gut microbiome manipulation is a potential strategy to improve cancer immunotherapy outcomes.

    Outlook:

    • Further research is needed to optimize microbiome-directed therapies.
    • Understanding specific microbial mechanisms will guide future treatment strategies for melanoma.

    More Related Videos

    Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

    Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

    Published on: February 10, 2023

    2.3K
    Preparation and Maintenance of Bioexclusion IsoPositive Cage Experiment for Human Fecal Transplantation into Germ-Free Mice07:45

    Preparation and Maintenance of Bioexclusion IsoPositive Cage Experiment for Human Fecal Transplantation into Germ-Free Mice

    Published on: February 28, 2025

    735

    Related Concept Videos

    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
    424
    Drugs for Treatment of Constipation-Predominant IBS01:21

    Drugs for Treatment of Constipation-Predominant IBS

    Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
    466
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    305